Scientists say a new malaria vaccine being tested in Mozambique
was successful in protecting infants less than 1 year old. The
study, published in The Lancet, was intended to show the safety
of the vaccine. GlaxoSmithKline researchers also found that the
full course of three shots reduced the risk of catching malaria
by 65 percent, The New York Times said. The efficacy data is
consistent with the estimate of 45 percent reduction in new
infections reported in a 2004 trial in Mozambique among children
one to four years old, GlaxoSmithKline said Thursday in a
release. "We're now a step closer to the realization of a
vaccine that can protect African infants," said Dr. Pedro
Alonso, the University of Barcelona professor who leads clinical
trials of the vaccine. Copyright 2007 by United Press
International Explore further: Acne pill benefits outweigh blood
clot risk: EU agency